Patents Assigned to Calitoga Pharmaceuticals, Inc.
  • METHODS OF TREATING HEMATOLOGICAL DISORDERS WITH QUINAZOLINONE COMPOUNDS IN SELECTED SUBJECTS
    Publication number: 20110306622
    Abstract: This disclosure relates to methods of selecting a subset of subjects having a hematological disorder and treating the selected group with a PI3K-delta inhibitor. In particular, the methods disclose evaluating levels of characteristic chemokine biomarkers, such as CCL2, CCL3, CCL4, CCL5, CXCL13, CCL17, CCL22, or TNF-alpha to select subjects that would have a greater chance of benefiting from treatment with a PI3K-delta inhibitor. The PI3K-delta inhibitors disclosed in this application are a type of quinazolinone-purinyl family of compounds.
    Type: Application
    Filed: June 10, 2011
    Publication date: December 15, 2011
    Applicant: Calitoga Pharmaceuticals, Inc.
    Inventors: Brian LANNUTTI, Langdon Miller, Heather Webb